登录新浪财经APP 搜索【信披】查看更多考评等级 本次授予865名激励对象共计1,024.4000万股限制性股票，股票来源均为公司从二级市场回购的本公司A 股普通股股票。经公司与上海证券交易所和中国证券登记结算有限责任公司上海分公司确认，上述已授 予的来源于二级市场回购的本公司A股普通股股票1,024.4000万股，股份性质将由无限售条件流通股变 更为有限售条件流通股。公司股本结构变更情况如下： 单位：股 ■ 证券代码：600216 证券简称：浙江医药 公告编号：2025-048 浙江医药股份有限公司 关于股份性质变更暨2025年限制性股票激励计划股份授予的 进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 鉴于浙江医药股份有限公司（以下简称"公司"或"浙江医药"） 2025年限制性股票激励计划（以下简 称"本激励计划"） 设定的激励对象获授限制性股票的条件已经成就，根据2025年11月13日召开的公司 2025年第一次临时股东会的授权，公司于2025年11月26日召开了第十届九次董事会会议，审议通过了 《关于向 ...

证券代码：600216 证券简称：浙江医药 公告编号：2025-048 浙江医药股份有限公司 关于股份性质变更暨 2025 年限制性股票激励计划股份授予的 进展公告 1 单位：股 | 证券类别 | 变更前股份数 | 本次变更股份数 | 变更后股份数 | | --- | --- | --- | --- | | 有限售条件流 通股份 | 4,275 | 10,244,000 | 10,248,275 | | 无限售条件流 通股份 | 961,633,475 | -10,244,000 | 951,389,475 | | 股份总数 | 961,637,750 | 0 | 961,637,750 | 注：实际股本结构变动情况以限制性股票登记完成后中国证券登记结算有限责任公司上海分 公司出具的股本结构表为准。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 鉴于浙江医药股份有限公司（以下简称"公司"或"浙江医药"） 2025 年 限制性股票激励计划（以下简称"本激励计划"） 设定的激励对象获授限制性股 票的条件已经成就，根据 20 ...

飞龙汽车部件股份有限公司（以下简称"公司"或"飞龙股份"）于2025年11月22日披露《关于公司控股股 东减持股份的预披露公告》（公告编号：2025-087），控股股东河南省宛西控股股份有限公司（以下简 称"宛西控股"）计划自公告之日起十五个交易日后的三个月内，以大宗交易方式减持公司股份不超过 11,495,700股（减持比例不超过公司总股本的2.0000%）。 公司于今日收到宛西控股出具的《减持公司股份告知函》，获悉宛西控股于2025年12月17日、12月18日 和12月25日通过大宗交易方式合计减持公司股份564.35万股，宛西控股及其一致行动人孙耀忠持有公司 股份比例由37.81%减少至36.83%，股份变动触及1%的整数倍。现就相关事项公告如下： ■ 特此公告。 登录新浪财经APP 搜索【信披】查看更多考评等级 飞龙汽车部件股份有限公司董事会 控股股东河南省宛西控股股份有限公司向本公司提供的信息内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 2025年12月25日 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 注：股权比例计算按四舍五入保留两位小数；如相关数据存在尾 ...

浙江医药：股东计划于1月16日至4月15日期间减持不超过公司2%的股份。 ...

Group 1 - Guangzhou Pharmaceutical Co., Ltd. announced a 500 million yuan acquisition of its wholly-owned subsidiary Zhejiang Pharmaceutical Industry Co., Ltd., marking the second major cross-province merger in the pharmaceutical distribution sector within a few days [1] - In 2024, Guangzhou Pharmaceutical is projected to achieve a main business revenue of 54.524 billion yuan, ranking 6th among national pharmaceutical wholesale companies, while Zhejiang Pharmaceutical is expected to generate 4.777 billion yuan, placing it 32nd [1] - The acquisition of Zhejiang Pharmaceutical is part of a broader trend where pharmaceutical distribution companies are expanding their business footprint beyond their home provinces through mergers and acquisitions [1][2] Group 2 - Zhejiang Pharmaceutical has a nationwide sales network covering 26 provinces, with a strong presence in Zhejiang, reaching 90% of county-level hospitals and hundreds of community health service centers [2] - Tailong Pharmaceutical's business includes drug formulation, traditional Chinese medicine, drug research services, and drug material distribution, with its subsidiary Tongquntang having a sales network across all 31 provinces and over 1 million acres of medicinal herb cultivation [2] - The top five companies in China's pharmaceutical wholesale industry, including China National Pharmaceutical Group and Shanghai Pharmaceuticals, have annual revenues exceeding 100 billion yuan, creating significant competitive pressure on smaller regional companies [2][4] Group 3 - Prior to the acquisition of Zhejiang Pharmaceutical, Guangzhou Pharmaceutical had already invested 749 million yuan to acquire 11.04% of Nanjing Pharmaceutical, becoming its second-largest shareholder [3] - Guangzhou Pharmaceutical is actively pursuing a strategy to "recreate a new Guangzhou Pharmaceutical," focusing on capital operations and expanding its industrial footprint through various acquisitions and partnerships [3] - The 2024 report on the pharmaceutical distribution industry indicates that as market growth slows, resource integration and scale advantages are becoming crucial for development [4]

截至12月8日收盘，青蒿素概念下跌0.51%，位居概念板块跌幅榜前列，板块内，德龙汇能、百花医 药、新和成等跌幅居前。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 共封装光学(CPO) | 4.72 | 天津自贸区 | -0.99 | | F5G概念 | 4.30 | 草甘膦 | -0.86 | | 光纤概念 | 3.67 | 青蒿素 | -0.51 | | 铜缆高速连接 | 3.57 | 煤炭概念 | -0.51 | | 福建自贸区 | 3.44 | 高股息精选 | -0.38 | | PET铜箔 | 3.02 | 超级品牌 | -0.34 | | 海南自贸区 | 3.00 | 金属锌 | -0.32 | | WiFi 6 | 3.00 | 大豆 | -0.31 | | 光刻机 | 3.00 | 啤酒概念 | -0.31 | | 海峡两岸 | 2.98 | 共享单车 | -0.29 | 资金面上看，今日青蒿素概念板块获主力资金净流出0.62亿元，其中，5股获主力资金净流出，净流出 资金居首的是德龙汇能， ...

浙江医药（600216.SH）12月5日在投资者互动平台表示，公司控股子公司新码生物至香港联交所上市 一事目前正在筹备中，仍有相当的不确定性。不论新码生物是否完成在香港联交所上市，公司目前并无 放弃新码生物控制权的计划，新码生物的财务报表将持续作为公司合并财务报表的一部分，新码生物也 将持续作为公司A股上市实体的组成部分。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司发布信息称"拟将抗癌药领域分拆为新码生物在联 交所上市"。公司拓宽融资渠道作为中小投资者本应该感到高兴，但上海主板市场股价长期低迷。投资 者希望抗癌药上市能够得到价值投资回报，但公司的做法让投资者丧失信心。 ...

Core Viewpoint - The company, Zhejiang Medicine, confirmed that it does not have any research or development projects related to influenza drugs or raw materials, although some of its antibiotic products are used in the clinical treatment of respiratory diseases [2] Company Summary - Zhejiang Medicine has indicated that its current research projects in clinical stages do not include any focus on influenza [2] - The company has some antibiotic products that are applied in the treatment of certain respiratory diseases [2]

人民财讯12月5日电，浙江医药(600216)12月5日在互动平台表示，公司对钠创新能源的投资属于财务投 资，该投资目前对公司合并财务报表的影响并不重大，公司并不参与钠创新能源的经营管理，也无相关 信息可供披露。 转自：证券时报 ...

Core Insights - The pharmaceutical-grade fish oil market is experiencing significant growth due to its high purity levels of EPA and DHA, which are crucial for cardiovascular disease prevention and brain health maintenance [1][3][4] - The global demand for pharmaceutical-grade fish oil is projected to increase, with sales expected to reach 31,400 tons in 2024, an increase of 5.9% from 2023 [3][4] - In China, the pharmaceutical-grade fish oil market is also expanding, with sales anticipated to reach 5,500 tons in 2024, reflecting a growth of 25% from the previous year [4] Industry Definition and Characteristics - Pharmaceutical-grade fish oil is derived from fatty fish and is characterized by its high concentration of omega-3 fatty acids, specifically EPA and DHA, which are validated for specific medical purposes [2][3] - Unlike regular dietary supplements, pharmaceutical-grade fish oil is a prescription-level treatment product with strong clinical evidence supporting its efficacy [2] Current Industry Status - The pharmaceutical-grade fish oil industry is witnessing a surge in demand driven by increasing health awareness among consumers, an aging population, and rising chronic disease rates [3][4] - The market is expected to see a steady increase in sales, with global sales projected to reach approximately 31,600 tons by 2025 [3] Industry Chain - The industry chain consists of upstream raw materials such as herring, mackerel, sardines, and tuna, which are processed into crude fish oil [5] - The midstream involves the production of pharmaceutical-grade fish oil, which has the highest technical barriers [5] - Downstream applications include pharmaceuticals, clinical nutrition, and high-end dietary supplements [5] Development Environment and Policies - The pharmaceutical-grade fish oil industry in China is supported by national policies aimed at promoting and regulating the sector, including standards for food safety and specific regulations for omega-3 fish oil products [6][7] Competitive Landscape - The Chinese pharmaceutical-grade fish oil market is characterized by competition among international pharmaceutical giants, leading domestic raw material and manufacturing companies, and health supplement brands [7][9] - The market is consolidating as stricter regulations and higher technical barriers drive competition towards leading players [7] Development Trends - The industry is moving towards a new phase characterized by high quality, strong evidence, precision, and globalization, with trends indicating a shift towards more precise, diversified, and evidence-based applications [11]